Conventus Biomedical Solutions, Inc.

CONVENTUS BIOMEDICAL SOLUTIONS, INC. is a privately-held, expert-level consulting firm specializing in regulatory strategies and requirements for biopharmaceutical products in early development stages through Phase 3. The Conventus team maintains offices in the Sorrento Valley area of San Diego and is led by Mr. Steven Kradjian, a Senior Regulatory Affairs professional who has led 27 successful IND filings at Conventus. Conventus' recent experience includes two biologics INDs in cardiovascular disease indications, and deep experience from planning the regulatory approach to expedite prudent development of biological and pharmaceutical products, to planning, writing, and filing these INDs with no clinical holds. In addition, Conventus has deep and recent experience working with FDA to address and resolve CMC issues for biological products in lyophilized dosage forms, mid-development formulation changes, potency method development for rDNA proteins, and negotiating carcinogenicity, pharmacology and toxicology requirements with FDA. SERVICES OFFERED • Global Regulatory Management • Quality Assurance/Change Control • CMC Biologics and Small Molecules • Pharmacology (PK/PD)/Toxicology Planning and Oversight • Clinical Operations • Regulatory Strategies for Biosimilars • Regulatory Strategies for Combination Products

Kintara Therapeutics, Inc. NASDAQ: KTRA

Our Fight Against Cancer Kintara Therapeutics is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara Therapeutics has teamed up with outstanding academic and clinical research institutions from around the world to support the development of our novel cancer therapies. A Pipeline of Breakthrough Cancer Therapeutics VAL-083 is a first-in-class small molecule DNA-targeting agent that exhibits a novel mechanism of action that results in DNA double strand breaks and cancer cell death. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types. VAL-083's indications include: Glioblastoma Multiforme (GBM) Ovarian Cancer Pediatric CNS Tumors REM-001 is a second generation photosensitizer drug possessing multiple advantages over earlier generation PDT compounds. REM-001's indications include: Cutaneous Metastatic Breast Cancer Recurrent Basal Cell Carcinoma Nevus Syndrome Hemodialysis Arteriovenous (AV) Access

PHASE ONE Foundation

Every cancer treatment starts with a Phase I clinical trial. PHASE ONE invests in the very best ideas and innovative research at the earliest stages, in all types of cancer, including rare types that are seriously underfunded.

Project Tomorrow

Bio Focus